Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853227 | 0.89 | HDAC8 (0.64) | HDAC8HDAC1HDAC2SIRT2FFAR1 | |
| SCHEMBL1851267 | 0.87 | HDAC8 (0.58) | HDAC8HDAC1HDAC2SIRT2FFAR1 | |
| SCHEMBL27659345 | 0.85 | L3MBTL1 (0.43) | HDAC8HDAC1HDAC2FFAR1 | |
| SCHEMBL4671678 | 0.83 | SPHK1 (0.45) | HDAC1HDAC2S1PR1SPHK1 | |
| SCHEMBL1857841 | 0.83 | HDAC8 (0.56) | HDAC8HDAC1HDAC2SIRT2FFAR1 | |
| SCHEMBL1854710 | 0.82 | HDAC1 (0.55) | HDAC8HDAC1HDAC2SIRT2FFAR1 | |
| SCHEMBL6725294 | 0.80 | S1PR1 (0.62) | HDAC8HDAC1HDAC2SIRT2S1PR2 | |
| Hydrochloric Acid SCHEMBL1856614 | 0.79 | S1PR1 (0.61) | HDAC8HDAC1HDAC2SIRT2S1PR2 | |
| SCHEMBL5047433 | 0.78 | SIRT2 (0.58) | HDAC8HDAC1HDAC2SIRT2FFAR1 | |
| SCHEMBL4670229 | 0.78 | TP53 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732534-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005082347-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | APLLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
| EP-1470102-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003064376-A1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | HDAC8 1977/4885HDAC1 2320/4885HDAC2 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.